International Stem Cell reports interim Phase I data for PD stem cell treatment

International Stem Cell Corp. (OTCQB:ISCO) reported interim 6-month data from the first cohort of patients in a Phase I trial to treat Parkinson's disease showing that 30 million human parthenogenetic stem cell (hpSC)-derived neuronal cells (ISC-hpNSC) led to no treatment-related serious adverse events reported.

The open-label, dose-escalation, Australian trial is enrolling 12 PD patients on stable levodopa across 3 dose cohorts to receive 30-70 million hpSC-derived neuronal cells injected intracerebrally into the striatum and substantia nigra...